{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:27:22Z","timestamp":1791919642122,"version":"4.3.4"},"reference-count":31,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In recent years, we have seen rapid expansion of chimeric antigen receptor T\u2010cell (CAR\u2010T) therapies in multiple malignancies. CAR\u2010T therapy has profoundly altered the treatment landscape of non\u2010Hodgkin lymphoma, B\u2010cell acute lymphoblastic leukemia, and multiple myeloma. Currently available CD19 and B\u2010cell maturation antigen\u2010directed CAR\u2010T therapies have shown high overall response rate and durable remissions in patients who have failed standard therapies. Multiple studies are underway exploring the role of CAR\u2010T\u2010cell therapy as earlier line of treatment. In high\u2010grade B\u2010cell lymphoma, CD19 CAR\u2010T therapy may replace autologous hematopoietic cell transplantation as second line therapy in near future. CAR\u2010T\u2010cell therapy targeting novel tumor\u2010associated antigens will help expand utility of this treatment modality in other hematological malignancies. It may also help overcome limitations of currently approved CAR\u2010T\u2010cell therapies. In this review, we have provided an overview of currently approved CAR\u2010T therapies and upcoming clinical trials which may potentially impact the clinical practice.<\/jats:p>","DOI":"10.1002\/jha2.338","type":"journal-article","created":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T08:53:24Z","timestamp":1637916804000},"page":"6-10","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":115,"title":["Overview of approved CAR\u2010T therapies, ongoing clinical trials, and its impact on clinical practice"],"prefix":"10.1002","volume":"3","author":[{"given":"Salyka","family":"Sengsayadeth","sequence":"first","affiliation":[{"name":"Vanderbilt Ingram Cancer Center Vanderbilt University Medical Center  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[{"name":"Vanderbilt Ingram Cancer Center Vanderbilt University Medical Center  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olalekan","family":"Oluwole","sequence":"additional","affiliation":[{"name":"Vanderbilt Ingram Cancer Center Vanderbilt University Medical Center  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[{"name":"Vanderbilt Ingram Cancer Center Vanderbilt University Medical Center  Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"issue":"8","key":"e_1_2_7_2_1","first-page":"878","article-title":"Axicabtagene ciloleucel: the first FDA\u2010approved CAR T\u2010cell therapy for relapsed\/refractory large B\u2010cell lymphoma","volume":"10","author":"King AC","year":"2019","journal-title":"J Adv Pract Oncol"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02104"},{"issue":"15","key":"e_1_2_7_6_1","doi-asserted-by":"crossref","first-page":"7515","DOI":"10.1200\/JCO.2021.39.15_suppl.7515","article-title":"Outcomes in ZUMA\u20105 with axicabtagene ciloleucel (axi\u2010cel) in patients (pts) with relapsed\/refractory (R\/R) indolent non\u2010Hodgkin lymphoma (iNHL) who had the high\u2010risk feature of progression within 24 months from initiation of first anti\u2010CD20\u2013containing chemoimmunotherapy (POD24)","volume":"39","author":"Jacobson CA","year":"2021","journal-title":"J Clin Ancol"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00375-2"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17197"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01222-8"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00507-2"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134449"},{"key":"e_1_2_7_17_1","unstructured":"GileadKite announces yescarta\u00ae CAR T\u2010cell therapy improved event\u2010free survival by 60% over chemotherapy plus stem cell transplant in second\u2010line relapsed or refractory large B\u2010cell lymphoma: businesswire. Available from:https:\/\/www.businesswire.com\/news\/home\/20210628005449\/en\/Accessedon November 15 2021."},{"key":"e_1_2_7_18_1","unstructured":"SquibbBMBristol Myers Squibb announces positive topline results from phase 3 TRANSFORM trial evaluating Breyanzi (lisocabtagene maraleucel) versus chemotherapy followed by stem cell transplant in second\u2010line relapsed or refractory large B\u2010cell lymphoma. 2021. Available from:https:\/\/bit.ly\/3zg9qx7. Accessed on November 15 2021."},{"key":"e_1_2_7_19_1","unstructured":"NovartisNovartis provides update on BELINDA study investigating Kymriah\u00ae as second\u2010line treatment in aggressive B\u2010cell non\u2010Hodgkin lymphoma: Novartis. 2021. Available from:https:\/\/bit.ly\/3pvLh38. Accessed on November 15 2021."},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS8053"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2021.101277"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.811.811"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186742"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01342"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00389"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002936"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14915"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8008"},{"issue":"6","key":"e_1_2_7_29_1","first-page":"316","article-title":"Advances in CAR T\u2010cell therapy for the treatment of multiple myeloma","volume":"18","author":"Shah N","year":"2020","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003848"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.338","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jha2.338","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.338","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T06:12:17Z","timestamp":1693203137000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":31,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1002\/jha2.338"],"URL":"https:\/\/doi.org\/10.1002\/jha2.338","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,24]]},"assertion":[{"value":"2021-10-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}